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IntroductIon
Androgen deficiency (AD) is a syndrome in which either 
androgen production or activity is reduced and can occur at 
any age. 
Reductions in androgen production may be physiological in 
aging, both in the ovaries and in the adrenal glands, especially 
reductions in dehydroepiandrosterone (DHEA) production1. 
However, in young women any type of reduction in androgens 
may be a sign of AD, as is observed in women who undergo 
oophorectomy , those who have hypogonadotropic hypogona-
dism, gonadal dysgenesis or adrenal dysfunction (Addison’s 
syndrome).  Furthermore, other conditions can also result in 
ethanol and also hyperthyroidism, pregnancy and liver cirrhosis2. 
This is because, by increasing levels of sex hormone binding 
globulin (SHBG), they can reduce free androgen levels3.
Female androgen deficiency began to be considered an 
important clinical entity in 2002, when a meeting held at the 
University of Princeton culminated in a consensus defining it 
as a syndrome consisting of reduced libido, reduced feeling of 
wellbeing or mood changes, persistent tiredness and inexplicable 
loss of bone mass, reduction in muscle strength, thinning of hair 
and altered cognitive function and memory4.
Although there is no data on the prevalence of this condition, it 
is estimated that 16 million North American women over the age 
of 50 have reduced libido (the syndrome’s principal symptom) 
and a significant proportion of them have reduced androgen 
concentrations in serum5. For this reason, many authors support 
increasing testosterone prescriptions, despite a lack of consensus 
regarding their efficacy for sexual dysfunction6. Furthermore, it 
should also be taken into account that prescribing testosterone 
without estrogens, does not provide benefits in terms of libido 
or coital frequency, irrespective of the route of administration7.
In response to the lack of consensus, this review began by 
searching for articles published between 1959 and May of 2010 
and indexed on PUBMED. This search identified a total of 105 
articles, 17 of which were chosen for analysis (four double blind 
placebo-controlled randomized studies of up to 4 months’ dura-
tion, eight bibliographic reviews and two specialists’ consensus 
statements). The primary objective of the review is to describe the 
practical features of diagnosing androgen deficiency syndrome 
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The evidence suggest that androgen deficiency in women induces sexual dysfunction as its 
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in the genesis of this disease, such as interpersonal relationships, social stressors, physical 
inactivity and the partner. The prevalence of sexual problems among women ranges from 9 
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and the options for treating this condition that significantly 
compromises women’s quality of life. 
tHe revIew
Androgens are C19 steroids that originate from cholesterol 
and the main sources of production in women are the adrenal 
glands, ovaries and peripheral tissues such as adipose, muscle 
and cutaneous tissues. Figure 1 illustrates steroidogenesis with 
rates of production and the organs involved. It will be observed 
that testosterone (T) is the end of the androgen pathway and 
that it is created by conversion of androstenedione (A) in the 
blood (50% from the ovaries, 25% from the adrenal glands and 
25% peripheral conversion).  In turn, dehydroepiandrosterone 
(DHEA) is the principal precursor of A and T androgens and is 
produced in the ovaries (20%) and adrenal glands (50%) and 
also derived from dehydroepiandrosterone sulphate  (DHEAS) 
in the blood (30%). During the post-menopause, DHEA, which 
is the primary source of androgens, suffers a 60% reduction, 
leading to hypoandrogenism, which can compromise the bones, 
muscles, brain, mammary glands and vagina and affect meta-
bolism of lipids, insulin and glucose8. 
In contrast with estradiol, which is an active steroid produced 
by the ovaries and which reaches all tissues, DHEA is an inactive 
precursor that is only transformed into active androgens in peri-
pheral tissues containing the enzymes necessary for continuation 
of the process of steroidogenesis and, as a result, each tissue 
type builds its own hormonal identity (intracrinology), avoiding 
unnecessary exposure to active circulating steroids9. In contrast 
with DHEA, the sulphate form, DHEAS, is lipophilic and, because 
it is unable to penetrate cells, it functions as a reserve pool. 
In turn, testosterone and its principal active metabolite 
(dihydrotestosterone -DHT) are more powerful androgens. Their 
biological effects are expressed by their free fraction, they are 
preferentially inactivated in the liver and excretion is fecal or renal. 
Diagnosis of female androgen deficiency is based on patient 
history, physical examination and laboratory results. Serum 
testosterone assay is an accessible test from an economic point 
of view, but its use is questionable because of the low specificity 
and sensitivity of the radioimmunoassay. Furthermore, it is inca-
pable of detecting extremely low testosterone levels and there is 
not yet a reference for normal levels in the female population10. 
Currently, the principal indication for serum testosterone assay is 
to monitor supraphysiological  concentrations during treatment. 
The gold standard for serum testosterone assay is to measure 
free testosterone by equilibrium dialysis, but its high cost and 
restricted availability means the test has limited applications. 
Despite all of these limitations and even in the knowledge 
that serum testosterone levels may not correspond with their 
biological activity (intracrinology), many authors still recommend 
their use in clinical practice and consider that levels of free testos-
terone ≤ ¼ of the normal level for the patient’s reproductive age 
are suggestive of androgen deficiency syndrome11.
The Princeton consensus suggests the diagnosis of AD and 
recommends that it should be treated when women with prema-
ture ovary failure or physiological menopause exhibit signs and 
symptoms including reduced libido, reduced feeling of wellbeing 
Figure 1 - steroidogenesis in the ovaries, adrenal glands and peripheral tissues of the principal hormones related to female sexual function 
E2= estradiol and DHT= dihydrotestosterone DHEA= dehydroepiandrosterone  
DHEAS= dehydroepiandrosterone sulphate A= androstenedione and T= testosterone
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or mood changes, persistent and unexplained tiredness, loss of 
bone mass, reduced muscle strength, thinning of hair and altered 
cognitive function and memory3 (Algorithm 1). 
The explanation for symptoms persisting among patients given 
appropriate conventional hormone therapy is based on reduced 
DHEA production in the adrenal glands and reduced enzyme 
activity to convert it into active steroids; and this is the reason that 
many authors believe that it is DHEA and not estrogen that is the 
physiological hormone that should be replaced after menopause11.
Although no androgens have been approved by the FDA (Food 
profile, altered liver function and, more rarely, changes in the 
pitch of voice, clitoromegaly and virilization of female fetuses 
if pregnancy occurs during treatment13. However, with appro-
priate doses of 300 mcg of testosterone per day, such effects 
are reported rarely.
There is also concern about the impact of testosterone and 
its metabolites on the breasts and endometrium of women who 
express aromatases in an abnormal manner. In this subset it is 
possible that a greater proportion of androgens are converted into 
estrogens, which would explain the increased oncogenic risk. 
Nevertheless, there is as yet no consensus in the literature with 
relation to these findings, since some epidemiological studies 
have demonstrated an increased risk whereas others did not 
detect this association13. Notwithstanding, it is recommended 
that women taking androgens should be monitored for cancer 
of the endometrium or breasts, following the same recommen-
dations as for conventional hormone treatment. 
Another question that remains to be answered relates to 
the possibility of cardiovascular risk when testosterone is admi-
nistered orally14, since studies have detected increases in LDL 
and reductions in HDL cholesterol and greater abdominal fat 
accumulation (androgenic pattern) promoting an increase in 
inflammatory cytokines and a reduction in adiponectin.
More recently, studies have been published on the use 
of testosterone patches15 with menopausal women that have 
demonstrated improvement in sexual function. Nevertheless, 
these results must be supplemented by assessments of the 
longer-term effects, indicating a need for further studies in this 
area. Additionally, this method is not yet available in Brazil and 
has not been approved by Anvisa.
Commercially available androgens
The most common routes of androgen administration are 
listed below. Neither, sublingual, buccal nor subcutaneous 
products are recommended by pharmaceutical surveillance 
authorities.
A) Injectable (industrial):
These may be oil-based, in which case release is slow, or 
they maybe ester-based, which makes free T rapidly available in 
circulation. These are marketed as different esters of testosterone, 
combined or not with estrogens. They involve an increased risk 
of exposure to supraphysiological doses, increasing the risk of 
adverse effects.
Testosterone decanoate is an anabolic steroid which has an 
indirect androgenic activity because it reduces SHBG levels and 
increases free testosterone. Administered (at a dosage of 50mg) 
every 40 days up to a maximum of six times per year, it is the 
safest option and is well tolerated by patients16. 
B) Oral (industrial or compounded):
When androgens are administered orally, they are rapidly 
metabolized by the liver, which may lead to hepatotoxicity and 
gastrointestinal disorders, in addition to reducing HDL and raising 
LDL cholesterol. Methyltestosterone is of greatest interest of the 
formulations available because it causes fewer gastrointestinal 
reactions and is better tolerated16. This product should be made 
up by a compounding pharmacist and the dosage varies from 
1.25mg to 2.5mg per day.
Other options include micronized testosterone and DHEA17.
E2= estradiol and DHT= dihydrotestosterone DHEA= dehydroepiandrosterone  
DHEAS= dehydroepiandrosterone sulphate A= androstenedione and T= testosterone
Does the patient have symptoms of androgen deficiency?
Yes No
Begin assessment
Continue assessment
Stress
Depression
Lifestyle
Metabolic and 
nutritional 
disorders
Is there a cause that explains the symptoms?
Yes
Yes
Yes
No
No
No
Treat cause
On conventional 
hormone therapy?
Begin estrogen replacement
QuestionableLaboratory diagnosis
+ - Alternative treatment
Causes that explain labora-
tory findings?
Use of 
pharmaceuticals
Consider 
androgen repla-
cement therapy
Treat specific cause
Algorithm 1 - Diagnosis of androgen deficiency
and Drugs Administration) for the treatment of female sexual 
dysfunction, an abusive number of prescriptions are issued on 
the basis of this complaint. Therefore, at the time of writing, 
sexual dysfunction treatment using androgen replacement is 
being carried out empirically, including in Brazil.
Authors who recommend treating with testosterone combine 
it with estrogen. Many of them have demonstrated efficacy for 
treating the symptoms of androgen deficiency, especially sexual 
dysfunction, vasomotor symptoms, bone mineral density and 
muscle strength12, and there are also studies that of observed that 
this combination reduces cardiovascular risk and the incidence 
of liver damage.10
Adverse effects that should be taken into account include 
acne, weight gain, increased facial hair, worsening of the lipid 
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C) Transdermal testosterone patches (industrial)17:
Each 28cm2 patch contains 8.4mg of testosterone and rele-
ases 300µg/day. Patches are the most physiological treatment 
option and should be changed every 3 or 4 days. Not yet available 
in Brazil or approved by Anvisa.
D) Topical testosterone (compounded)17:
Testosterone propionate cream, 1% to 2% in white petroleum 
jelly, is a good option and should be applied to the clitoris and 
labia minora daily. 
conclusIons
Despite the reports of beneficial effects on sexual dysfunction 
and other symptoms of AD syndrome and despite its short-term 
safety being well-established (6 months), the long-term effects 
of androgen therapy are not well-documented17.
Menopausal women with androgen deficiency syndrome are 
one of the most important applications for androgen therapy 
because the treatment improves quality of life. Physicians who 
judge the treatment to be necessary should inform their patients 
about possible risks and adverse effects and the efficacy of treat-
ment. When prescribing, care must be taken with the dosage, 
route of administration and length of treatment and lipids should 
be controlled rigorously and breasts and liver must be monitored. 
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